Synergistic Activity of Fosfomycin, Ciprofloxacin, and Gentamicin Against Escherichia coli and Pseudomonas aeruginosa Biofilms
Gram-negative (GN) rods cause about 10% periprosthetic joint infection (PJI) and represent an increasing challenge due to emergence of antimicrobial resistance. Escherichia coli and Pseudomonas aeruginosa are among the most common cause of GN-PJI and ciprofloxacin is the first-line antibiotic. Due t...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-11-01
|
Series: | Frontiers in Microbiology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fmicb.2019.02522/full |
id |
doaj-7076c73446144e458a50c74e7d98fc63 |
---|---|
record_format |
Article |
spelling |
doaj-7076c73446144e458a50c74e7d98fc632020-11-25T01:50:35ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2019-11-011010.3389/fmicb.2019.02522489023Synergistic Activity of Fosfomycin, Ciprofloxacin, and Gentamicin Against Escherichia coli and Pseudomonas aeruginosa BiofilmsLei Wang0Lei Wang1Mariagrazia Di Luca2Tamta Tkhilaishvili3Tamta Tkhilaishvili4Andrej Trampuz5Andrej Trampuz6Mercedes Gonzalez Moreno7Mercedes Gonzalez Moreno8Center for Musculoskeletal Surgery, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, GermanyBerlin-Brandenburg Center for Regenerative Therapies, Charité – Universitätsmedizin Berlin, Berlin, GermanyCenter for Musculoskeletal Surgery, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, GermanyCenter for Musculoskeletal Surgery, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, GermanyBerlin-Brandenburg Center for Regenerative Therapies, Charité – Universitätsmedizin Berlin, Berlin, GermanyCenter for Musculoskeletal Surgery, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, GermanyBerlin-Brandenburg Center for Regenerative Therapies, Charité – Universitätsmedizin Berlin, Berlin, GermanyCenter for Musculoskeletal Surgery, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, GermanyBerlin-Brandenburg Center for Regenerative Therapies, Charité – Universitätsmedizin Berlin, Berlin, GermanyGram-negative (GN) rods cause about 10% periprosthetic joint infection (PJI) and represent an increasing challenge due to emergence of antimicrobial resistance. Escherichia coli and Pseudomonas aeruginosa are among the most common cause of GN-PJI and ciprofloxacin is the first-line antibiotic. Due to emergence of fluoroquinolone resistance, we evaluated in vitro the activity of fosfomycin, ciprofloxacin, and gentamicin, alone and in combinations, against E. coli and P. aeruginosa biofilms. Conventional microbiological tests and isothermal microcalorimetry were applied to investigate the anti-biofilm activity of the selected antibiotics against standard laboratory strains as well as clinical strains isolated from patients with prosthetic joint associated infections. The biofilm susceptibility to each antibiotic varied widely among strains, while fosfomycin presented a poor anti-biofilm activity against P. aeruginosa. Synergism of two-pair antibiotic combinations was observed against different clinical strains from both species. Highest synergism was found for the fosfomycin/gentamicin combination against the biofilm of E. coli strains (75%), including a gentamicin-resistant but fosfomycin-susceptible strain, whereas the gentamicin/ciprofloxacin combination presented synergism with higher frequency against the biofilm of P. aeruginosa strains (71.4%). A hypothetical bacteriolysis effect of gentamicin could explain why combinations with this antibiotic seem to be particularly effective. Still, the underlying mechanism of the synergistic effect on biofilms is unknown. In conclusion, combinatorial antibiotic application has shown to be more effective against biofilms compared to monotherapy. Further in vivo and clinical studies are essential to define the potential treatment regimen based on our results.https://www.frontiersin.org/article/10.3389/fmicb.2019.02522/fullEscherichia coliPseudomonas aeruginosabiofilm-associated infectionantibiotic activitysynergismclinical isolates |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lei Wang Lei Wang Mariagrazia Di Luca Tamta Tkhilaishvili Tamta Tkhilaishvili Andrej Trampuz Andrej Trampuz Mercedes Gonzalez Moreno Mercedes Gonzalez Moreno |
spellingShingle |
Lei Wang Lei Wang Mariagrazia Di Luca Tamta Tkhilaishvili Tamta Tkhilaishvili Andrej Trampuz Andrej Trampuz Mercedes Gonzalez Moreno Mercedes Gonzalez Moreno Synergistic Activity of Fosfomycin, Ciprofloxacin, and Gentamicin Against Escherichia coli and Pseudomonas aeruginosa Biofilms Frontiers in Microbiology Escherichia coli Pseudomonas aeruginosa biofilm-associated infection antibiotic activity synergism clinical isolates |
author_facet |
Lei Wang Lei Wang Mariagrazia Di Luca Tamta Tkhilaishvili Tamta Tkhilaishvili Andrej Trampuz Andrej Trampuz Mercedes Gonzalez Moreno Mercedes Gonzalez Moreno |
author_sort |
Lei Wang |
title |
Synergistic Activity of Fosfomycin, Ciprofloxacin, and Gentamicin Against Escherichia coli and Pseudomonas aeruginosa Biofilms |
title_short |
Synergistic Activity of Fosfomycin, Ciprofloxacin, and Gentamicin Against Escherichia coli and Pseudomonas aeruginosa Biofilms |
title_full |
Synergistic Activity of Fosfomycin, Ciprofloxacin, and Gentamicin Against Escherichia coli and Pseudomonas aeruginosa Biofilms |
title_fullStr |
Synergistic Activity of Fosfomycin, Ciprofloxacin, and Gentamicin Against Escherichia coli and Pseudomonas aeruginosa Biofilms |
title_full_unstemmed |
Synergistic Activity of Fosfomycin, Ciprofloxacin, and Gentamicin Against Escherichia coli and Pseudomonas aeruginosa Biofilms |
title_sort |
synergistic activity of fosfomycin, ciprofloxacin, and gentamicin against escherichia coli and pseudomonas aeruginosa biofilms |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Microbiology |
issn |
1664-302X |
publishDate |
2019-11-01 |
description |
Gram-negative (GN) rods cause about 10% periprosthetic joint infection (PJI) and represent an increasing challenge due to emergence of antimicrobial resistance. Escherichia coli and Pseudomonas aeruginosa are among the most common cause of GN-PJI and ciprofloxacin is the first-line antibiotic. Due to emergence of fluoroquinolone resistance, we evaluated in vitro the activity of fosfomycin, ciprofloxacin, and gentamicin, alone and in combinations, against E. coli and P. aeruginosa biofilms. Conventional microbiological tests and isothermal microcalorimetry were applied to investigate the anti-biofilm activity of the selected antibiotics against standard laboratory strains as well as clinical strains isolated from patients with prosthetic joint associated infections. The biofilm susceptibility to each antibiotic varied widely among strains, while fosfomycin presented a poor anti-biofilm activity against P. aeruginosa. Synergism of two-pair antibiotic combinations was observed against different clinical strains from both species. Highest synergism was found for the fosfomycin/gentamicin combination against the biofilm of E. coli strains (75%), including a gentamicin-resistant but fosfomycin-susceptible strain, whereas the gentamicin/ciprofloxacin combination presented synergism with higher frequency against the biofilm of P. aeruginosa strains (71.4%). A hypothetical bacteriolysis effect of gentamicin could explain why combinations with this antibiotic seem to be particularly effective. Still, the underlying mechanism of the synergistic effect on biofilms is unknown. In conclusion, combinatorial antibiotic application has shown to be more effective against biofilms compared to monotherapy. Further in vivo and clinical studies are essential to define the potential treatment regimen based on our results. |
topic |
Escherichia coli Pseudomonas aeruginosa biofilm-associated infection antibiotic activity synergism clinical isolates |
url |
https://www.frontiersin.org/article/10.3389/fmicb.2019.02522/full |
work_keys_str_mv |
AT leiwang synergisticactivityoffosfomycinciprofloxacinandgentamicinagainstescherichiacoliandpseudomonasaeruginosabiofilms AT leiwang synergisticactivityoffosfomycinciprofloxacinandgentamicinagainstescherichiacoliandpseudomonasaeruginosabiofilms AT mariagraziadiluca synergisticactivityoffosfomycinciprofloxacinandgentamicinagainstescherichiacoliandpseudomonasaeruginosabiofilms AT tamtatkhilaishvili synergisticactivityoffosfomycinciprofloxacinandgentamicinagainstescherichiacoliandpseudomonasaeruginosabiofilms AT tamtatkhilaishvili synergisticactivityoffosfomycinciprofloxacinandgentamicinagainstescherichiacoliandpseudomonasaeruginosabiofilms AT andrejtrampuz synergisticactivityoffosfomycinciprofloxacinandgentamicinagainstescherichiacoliandpseudomonasaeruginosabiofilms AT andrejtrampuz synergisticactivityoffosfomycinciprofloxacinandgentamicinagainstescherichiacoliandpseudomonasaeruginosabiofilms AT mercedesgonzalezmoreno synergisticactivityoffosfomycinciprofloxacinandgentamicinagainstescherichiacoliandpseudomonasaeruginosabiofilms AT mercedesgonzalezmoreno synergisticactivityoffosfomycinciprofloxacinandgentamicinagainstescherichiacoliandpseudomonasaeruginosabiofilms |
_version_ |
1725001040665772032 |